房颤诊断时机与亚型对急性缺血性卒中早期抗凝影响的亚组分析
OPTIMAS试验亚组分析纳入3619例急性缺血性卒中合并房颤患者,按房颤诊断时机(卒中前/后)和亚型(持续性/阵发性)分层,比较早期(4天内)与延迟(7-14天)启动直接口服抗凝药的效果。结果显示房颤诊断时机或亚型均未显著改变早期与延迟抗凝的疗效(交互作用P值分别为0.312和0.377)。持续性房颤较阵发性房颤与主要结局风险独立相关(校正OR 2.10,95%CI 1.19-3.68)。
要点
- 房颤诊断时机(卒中前或后)不影响早期与延迟DOAC的疗效比较。
- 房颤亚型(持续性或阵发性)不影响早期与延迟DOAC的疗效比较。
- 持续性房颤患者主要结局风险约为阵发性房颤的2倍(校正OR 2.10)。
核心结论
- 未发现房颤诊断时机或亚型改变早期与延迟DOAC治疗效果的证据。
- 持续性房颤与主要结局风险增加独立相关,约为阵发性房颤的2倍。
研究设计与样本
- OPTIMAS试验为随机、平行组、开放标签、盲法结局评估的研究。
- 纳入3619例急性缺血性卒中合并房颤患者,平均年龄78.0±9.9岁,女性占45.3%。
- 患者1:1随机接受早期(4天内)或延迟(第7-14天)DOAC启动。
主要发现
- 卒中前诊断房颤者中,早期DOAC组主要结局事件37/918(4.0%),延迟组32/920(3.5%),OR 1.17(95%CI 0.72-1.89)。
- 卒中后诊断房颤者中,早期DOAC组主要结局事件22/895(2.5%),延迟组27/886(3.0%),OR 0.79(95%CI 0.45-1.40),交互作用P=0.312。
- 持续性房颤与阵发性房颤的早期vs延迟DOAC OR分别为1.06(95%CI 0.71-1.58)和0.66(95%CI 0.25-1.72),交互作用P=0.377。
- 持续性房颤较阵发性房颤与主要结局风险独立相关,校正OR 2.10(95%CI 1.19-3.68)。
- 房颤诊断时机与结局事件无显著关联。
临床怎么用
- 对于急性缺血性卒中合并房颤患者,早期(4天内)启动DOAC的决策可不因房颤诊断时机或亚型而改变。
- 持续性房颤患者可能需更密切监测或强化二级预防,因其主要结局风险较高。
局限性
- 本研究为亚组分析,可能把握度不足。
- 开放标签设计可能引入偏倚,尽管结局评估采用盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After acute ischemic stroke, it is uncertain whether the time of atrial fibrillation (AF) diagnosis (before or after stroke) or AF subtype (paroxysmal or permanent) modifies the treatment effect of early versus delayed direct oral anticoagulant (DOAC) initiation. METHODS: OPTIMAS (Optimal Timing of Anticoagulation After Acute Ischemic Stroke) was a randomized, parallel-group, open-label trial with blinded outcome assessment. Participants with acute ischemic stroke and AF were randomized 1:1 to early (within 4 days) or delayed (day 7-14) DOAC initiation. The primary outcome was a composite of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and systemic arterial embolism. In this trial subgroup analysis, the prespecified subgroup of interest was time of AF diagnosis, classified as before or after the qualifying stroke. We also investigated AF subtype classified as persistent or paroxysmal. We fitted mixed effects logistic regression models with interaction terms between each subgroup and treatment allocation. We also investigated associations between AF time of diagnosis or subtype and outcomes using multivariable logistic regression. RESULTS: We included 3619 participants (mean age 78.0±9.9 years; 45.3% women). For AF diagnosed before stroke, 37 of 918 (4.0%) participants allocated to early DOAC had a primary outcome event versus 32 of 920 (3.5%) allocated to delayed DOAC, odds ratio, 1.17 (95% CI, 0.72-1.89), while for AF diagnosed after stroke the respective primary outcome rates were 22 of 895 (2.5%) and 27 of 886 (3.0%; odds ratio, 0.79 [95% CI, 0.45-1.40], Pinteraction=0.312). AF subtype did not modify the treatment effect, with odds ratios (95% CIs) for early versus late DOAC for persistent and paroxysmal AF of 1.06 (0.71-1.58) and 0.66 (0.25-1.72), respectively, Pinteraction=0.377. AF time of diagnosis was not associated with outcome events. Compared with paroxysmal AF, persistent AF was independently associated with an increased risk of the primary outcome (adjusted odds ratio, 2.10 [95% CI, 1.19-3.68]). CONCLUSIONS: We found no evidence that AF time of diagnosis or subtype modify the effects of early DOAC treatment. Persistent AF was independently associated with approximately double the risk of the primary outcome compared with paroxysmal AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03759938.
引用
- Lyon J, Nash PS, Ahmed N, et al. Early Versus Delayed Anticoagulation in Acute Ischemic Stroke According to Atrial Fibrillation Subtype and Time of Diagnosis: Subgroup Analysis of the OPTIMAS Randomized Controlled Trial. Stroke. 2026. PMID: 41919368. doi:10.1161/STROKEAHA.125.055037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。